We are currently rebuilding the Noventure website to reflect our evolving strategy and global focus

For the third consecutive year, Noventure has participated in the annual congress of the EAU - European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,…

We are pleased to announce the launch of Rhinosectan® in its first market, Spain.

Rhinosectan® is based on Xyloglucan, a mucomimetic agent that forms a protective barrier over the nasal…

Beneficial effect of the combination of pea protein and grape seed extract in a murine model of vulvovaginal candidiasis.

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018.

Pediatric gastroenterologists are a key target group for the…

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and…